Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
German Pharmaceutical Pricing: Lessons for the United States
Marc A. Rodwin, Sara Gerke
Penn State Cancer Institute
Cancer Institute, Cancer Control
Dickinson Law (Carlisle)
Research output
:
Contribution to journal
›
Article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'German Pharmaceutical Pricing: Lessons for the United States'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
United States
100%
New Drugs
100%
Pharmaceutical Pricing
100%
Reimbursement
66%
Germany
66%
Added Benefit
66%
Patient Access
33%
Inflation
33%
First Year
33%
Selling
33%
13th
33%
European Countries
33%
Private Health Insurance
33%
National Associations
33%
Patient Benefit
33%
Federal Programs
33%
Marketing Approval
33%
Private Insurers
33%
Co-payment
33%
Reference Price
33%
Drug Pricing
33%
Pharmaceutical Expenditure
33%
Federal Joint Committee
33%
Price Cap
33%
Price Resolution
33%
Pharmaceutical Market
33%
Benefit Assessment
33%
Pricing Reform
33%
Statutory Health Insurance
33%
Health Insurance Fund
33%
Arbitration Board
33%
Economics, Econometrics and Finance
Price
100%
Pricing
100%
Marketing
20%
Inflation
20%
Private Insurance
20%
Arbitration
20%
Health Insurance
20%
Price Regulation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Market
100%